Welcome to our dedicated page for Nrx Pharmaceuticals news (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on Nrx Pharmaceuticals stock.
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company whose news flow centers on its NMDA-based drug pipeline and interventional psychiatry operations. Company announcements frequently highlight progress with NRX-100, a preservative-free intravenous ketamine formulation, and NRX-101, an oral D-cycloserine/lurasidone combination, both aimed at serious central nervous system disorders such as suicidal depression and suicidal bipolar depression.
Investors following NRXP news can expect updates on FDA interactions, including Fast Track and Breakthrough Therapy designations, Abbreviated New Drug Application (ANDA) milestones for preservative-free ketamine, and New Drug Application (NDA) activities. The company also reports on the use of large Real World Evidence datasets to support potential Accelerated Approval pathways for NRX-100 in suicidal ideation associated with depression and bipolar depression.
Another recurring theme in NRx Pharmaceuticals’ news is the expansion of its HOPE Therapeutics subsidiary, which operates interventional psychiatry clinics. Releases describe clinic acquisitions, strategic interests in practices, and deployment of treatments such as ketamine-based therapies, Transcranial Magnetic Stimulation (TMS), Hyperbaric Oxygen Therapy, and digital therapeutics for suicidal depression, PTSD, and related conditions. Updates often cover new treatment protocols that combine TMS with D-cycloserine and other medications.
NRXP news items also include corporate developments such as conference presentations, corporate update calls, financing transactions, and changes in independent registered public accounting firms, as reflected in SEC filings. For investors and observers, the news stream provides ongoing insight into NRx Pharmaceuticals’ clinical progress, regulatory steps, clinic network growth, and capital markets activity related to its focus on Neuroplastic Therapies and suicidal depression.
NRx Pharmaceuticals announced that it will report its third quarter 2022 financial results on November 14, 2022, before the market opens. A conference call and webcast will take place at 8:00 AM ET on the same day to discuss the results and provide updates on clinical and corporate matters. Interested participants can access the call via telephone or through a live webcast on the company's website. The company is known for its lead program, NRX-101, which targets bipolar depression and has received regulatory designations aimed at expediting its development.
NRx Pharmaceuticals has transitioned to U.S.-based manufacturing for its investigational drug NRX-101, targeting suicidal bipolar depression. The FDA has received updated manufacturing files, facilitating an upcoming Phase 3 trial aimed at patients with acute suicidal ideation. The drug, a combination of D-cycloserine and lurasidone, has been shown to significantly reduce both depression and suicidality in previous trials. This new capability could expedite the drug's market launch while addressing a critical unmet need in mental health care.
NRx Pharmaceuticals (Nasdaq: NRXP) has secured approximately $11 million in unsecured debt financing from Streeterville Capital, aimed to boost the development of its lead drug NRX-101 for treating suicidal bipolar depression and PTSD. With about $10 million earmarked for these programs, the funds will also support corporate operations. The financing comes with a 9% interest rate and a maturity of 18 months. The company is optimistic about the potential of NRX-101, especially after achieving FDA milestones including Breakthrough Therapy Designation.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced that CEO Stephen Willard and executives will provide a corporate update at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 9:00 AM ET. This presentation will cover the company’s progress, particularly focusing on NRX-101, a novel treatment for severe bipolar depression. NRX-101 has received FDA Breakthrough Therapy designation and is expected to begin its registration trial in Q4 2022. The event is accessible via webcast with a replay available for 30 days.
NRx Pharmaceuticals (Nasdaq: NRXP) hosted its Q2 2022 earnings call on August 15, 2022, announcing financial results and clinical updates. The company is focused on its lead compound NRX-101, which has received Breakthrough Therapy designation from the FDA for severe bipolar depression with acute suicidal ideation. A Phase 2 trial for NRX-101 has commenced, aiming for data readout by early 2023. Q2 2022 net loss was $7.0 million, an increase from $0.1 million in Q2 2021, while cash reserves decreased to $24.5 million. The company plans to maintain operations through August 2023.
Summary not available.
NRx Pharmaceuticals, based in Radnor, PA, will announce its second quarter 2022 financial results on August 15, 2022, before market open. A conference call will follow at 8:30 AM ET, offering a corporate and clinical update along with a Q&A session. Investors can submit questions via email by 4:00 PM ET on August 12. The call can be accessed by dialing (844) 826-3033 (U.S.) or (412) 317-5185 (International) and the replay will be available on the company's website afterwards.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) appointed Stephen Willard as CEO and Board member, succeeding interim CEO Robert Besthof, who returns to his previous roles. Willard, a veteran in biotechnology management, previously led Cellphire Therapeutics and Flamel Technologies. His expertise includes law and finance, and he’s a National Science Board appointee (2018-2024). Under Willard’s leadership, NRx aims to advance NRX-101, a promising treatment for bipolar depression and acute suicidal ideation, with plans for FDA registration trials.
NRx Pharmaceuticals announced that the FDA has declined to issue an Emergency Use Authorization for ZYESAMI® (aviptadil) for a subgroup of critically ill COVID-19 patients who were also treated with Remdesivir. This decision follows the previously communicated futility of the ACTIV-3b / TESICO Study. The company will now focus on the development of NRX-101, a treatment for bipolar depression with suicidality. Despite the setback with ZYESAMI®, NRX-101 has received Breakthrough Therapy designation from the FDA, indicating ongoing potential for future development.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced that the FDA denied its request for Breakthrough Therapy designation for ZYESAMI (aviptadil). The decision comes despite positive findings from a post-hoc analysis in patients with Critical COVID-19. The company is now focusing on advancing NRX-101, a BTD compound for Bipolar Depression with suicidal ideation, with topline data expected by year-end. NRx plans to explore ZYESAMI for other indications. The interim CEO expressed disappointment but reaffirmed the commitment to address high unmet patient needs.